

**AREA PRESCRIBING COMMITTEE – ACTION LIST 16<sup>th</sup> AUGUST 2018**

Action Reference	Minute Reference	ACTION	OWNER	FURTHER COMMENTS	TARGET DATE	STATUS (R/A/Clear)
<b>ACTIONS 2017</b>						
15/17	28/17	<b>Woundcare review</b> – Cumbria RDTC report for Wound care to be forwarded to the Tissue Viability group for review and explanation of dressing cost and choice and proposals for reducing spend and/or volume Tissue Viability group to audit the use of antibiotic and honey dressings for clinical appropriateness.	HH	Audit and results are due to be reviewed at the October 2018 APC meeting.	11.10.2018	ONGOING
53/17	89/17	<b>NTAG – Paliperidone long acting injection (Xepilon®) and Paliperidone 3 monthly injection (Trevicta®) for schizophrenia</b> – Paliperidone 3 monthly injection (Trevicta®) RECOMMENDED as per its licensed indications. – RED CPFT to update SCG alongside this recommendation.	HH	CPFT awaiting clear guidance until updating on how the SCG's system will operate when we move across to the North of Tyne APC and Formulary. ONGOING until decision is made.		ONGOING
60/17	98/17	<b>Mesalazine MR prescribing</b> – NCUHT asked primary care to support a switching programme of all Mesalazine MR prescribing to be prescribed by brand with Octasa MR being the first line option.	HG	NA to ask consultants for feedback on how they wish to proceed.	11.10.2018	ONGOING
72/17	116/17	<b>Guidelines for the monitoring of IMD's</b> Guidelines still in DRAFT format, NECS MO pharmacist to complete for the NE & Cumbria.	HS	To be brought to the October 2018 APC meeting.	11.10.2018	ONGOING
<b>ACTIONS 2018</b>						
04/18	13/18	<b>Metolazone and Ranolazine prescribing</b> — Request from secondary care for Metolazone to be prescribed in primary care under the care of secondary care. Also a request to review the prescribing of Ranolazine.	JF	The Metolazone Prescribing guideline is currently being updated to contain comments and further information around the monitoring aspects. To be brought to the October 2018 APC meeting.	11.10.2018	ONGOING

05/18	16/18	<b>TA511</b> Brodalumab - Treating moderate to severe plaque psoriasis -RED	HG	Bluteq form to be added	11.10.2018	ONGOING
08/18	17/18	<b>NG89:</b> Venous thromboembolism in over 16's: reducing the risk of hospital-acquired DVT or PE – Noted – Secondary care to review prescribing policy in conjunction with pre-assessment team.	JF	Noted – Clive Graham NCUHT is now leading on this review within NCUHT. new protocol and local guideline to be written. JF to take over this action in BG absence.	11.10.2018	ONGOING
18/18	43/18	<b>Colomycin nebulisers SCG</b> – Licensed product is now readily available for the treatment of adults with bronchiectasis so an Amber RAG rating with shared care is requested.	JF	BG to feedback to John Atkinson that a patient leaflet is required and also to confirm the patient review arrangements. The sundries needed on the SCG also to be reviewed to see what is exactly is required as these may not be available in primary care. JF to follow up.	11.10.2018	ONGOING
24/18	55/18	<b>Transition to North of Tyne APC</b> Formulary review details to be issued to all NCUHT, CPFT and NECS Pharmacists for completion over June / July 2018.	HG JF	Formulary review details to be issued to all NCUHT, CPFT and NECS Pharmacists, this will be done over Sept 18. Details of formulary differences to be brought to the Oct 18 APC meeting for review.	11.10.2018	ONGOING
26/18	60/18	<b>Insulin Degludec (Tresiba®)- Paediatric use</b> who cannot tolerate the sting associated with insulin glargine and in children and adolescents requiring supervised administration / flexibility around administration times. AMBER in line with North of Tyne	PU	PU to inform paediatrics.	11.10.2018	
27/18	60/18	<b>Aviptadil with phentolamine mesilate (Invicorp®)</b> - For the symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic or mixed aetiology. Noted – AMBER in line with North of Tyne	HG	HG to review North Cumbria CCG guidance.	11.10.2018	
28/18	61/18	<b>TA521</b> Guselkumab – Treating moderate to severe plaque psoriasis. – CCG commissioned -RED.	PU	Bluteq form to be added	11.10.2018	

29/18	61/18	<b>TA534</b> Dupilumab - Treating moderate to severe atopic dermatitis - CCG commissioned -RED.	PU	Bluteq form to be added Noted 30 day implementation for CCG's	11.10.2018	
30/18	61/18	<b>TA537</b> Ixekizumab - Treating active psoriatic arthritis after inadequate response to DMARDS - CCG commissioned	PU	Bluteq form to be added	11.10.2018	
31/18	62/18	<b>NG97:</b> Dementia: assessment, management and support for people living with dementia and their carers. - Current SCG review to be done by CPFT and ICC leads to bring into line with this new guidance.		Noted to be added to Prescription Pad	11.10.2018	
32/18	62/18	<b>NG98:</b> Hearing loss in adults: assessment and management.	PU	Noted to be added to Prescription Pad	11.10.2018	
33/18	62/18	<b>NG100:</b> Rheumatoid arthritis in adults: management	PU	- Noted to be added to prescription pad the lack of evidence to support methotrexate injections.	11.10.2018	
34/18	65/18	Sodium Valproate PREVENT programme currently being rolled out across North Cumbria. Practice patient data to be collated by the 31 <sup>st</sup> August 2018, this to be sent to CPFT for review.	HH	HH to identify who in CPFT is the clinical lead to receive this data.	11.10.2018	
35/18	66/18	<b>Palliative Care Formulary RAG rating review</b> – Jo Thomas, Specialist Pharmacist Community Services, CPFT presented the committee with a list of common drugs used currently in Palliative care across North Cumbria. She showed the current North Cumbria RAG rating, the proposed current North of Tyne RAG formulary RAG rating and any differences / queries relating to each drug for its prescribing. The committee reviewed each drug separately and the decision on the most appropriate RAG rating was made.	PU	PU to update current RAG list.	11.10.2018	
36/18	67/18	<b>Midazolam 10mg/2ml availability at NCUHT</b> – Jo Thomas, Specialist Pharmacist Community Services, CPFT presented the committee with the paper outlining the request to have Midazolam 10mg/2ml injection as stock in certain clinical areas with NCUHT to treat palliative care patients. BG informed the committee that the patient safety panel within NCUHT decided that all Midazolam 10mg/2ml injection be supplied on a named basis only against a prescription chart,	JF	BG and JF to feedback to the areas / wards where palliative care patients are to be treated to prescribe this drug for these patients earlier in their treatment pathway in the anticipation of its use.	11.10.2018	

		no stock to be held on any ward. This was due to a patient safety incident in the past.				
37/18	68/18	<b>Insulin passport</b> – The committee reviewed the insulin passport process and actual card and information sheets for patients, agreed that this would give patient choice across Cumbria, however it was noted that it would be the patient’s responsibility to carry this card / information with up to date dose regimes.	HH HG	Further feedback to be brought to the October 2018 APC meeting from Cumbria Diabetes on how the passports will be issued to patients and from Community Pharmacies on their views of the scheme. HH to ask the diabetic champions within CPFT for their thoughts.	11.10.2018	
38/18	70/18	<b>Buccal Midazolam &amp; Rectal Diazepam guideline</b> – Guideline reviewed by the committee, APPROVED for use across North Cumbria. Noted that GP’s will receive a copy of the patient’s plan from CPFT.	HH PU	To be added to both Prescription Pad and CPFT Intranet.	11.10.2018	
39/18	71/18	<b>FreeStyle Libre supply</b> – AL informed the committee that she has received an email from a Cumbria Diabetes consultant stating that all supplies of FreeStyle Libre to patients across North Cumbria have currently stopped, this being due to a shortage of personnel to issue the prescriptions.	JF HH	Both HH and BG have been asked to take this back to their respective trusts to look at the issues involved and move the process forward as this was the agreed pathway for FreeStyle Libre supply.	11.10.2018	
40/18	86/18	<b>Drug Safety Update (July 2018)</b>	PU	Point 2 to be added to Prescription pad.	11.10.2018	
41/18	89/18	<b>ADHD in Adults Shared Care Guideline – North Cumbria</b> – The newly commissioned service across North Cumbria will use this SCG to cover all adult patients.	PU	To be added to NECS MO website and Prescription Pad.	11.10.2018	

	New action from current meeting
	Action over one meeting old
	Action over two meetings old